摘要
胰岛B细胞功能受损和胰岛素抵抗是2型糖尿病的两个重要发病机制。B细胞功能受损又与B细胞数量减少密切相关。因此，增加和维持B细胞数量，保护B细胞功能的治疗方案，如使用GLP-1类似物，将为2型糖尿病的对因治疗提供新的选择。
出处
《药品评价》
CAS
2009年第4期142-143,共2页
Drug Evaluation
同被引文献13
-
1邢万佳,张胜兰.胰高糖素样肽-1及其类似物在糖尿病治疗中的研究进展[J].中国医药,2006,1(2):126-128. 被引量：2
-
2Drucker D J. Development of glueagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes[ J ]. Curr Pharm Des ,2001,7 (14) : 1399-1412.
-
3Mu J, Woods J, Zhou Y P, et al. Chronic inhibition of dipetidy1 peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes ,2006,55 ( 6 ) : 1695-1704.
-
4Baggio L L, Drucker D J. Clinical endocrinology and metabolism. Glucagon-like peptidc-1 and glucagon-like peptide-2 [ J ]. Best Pract Res Clin Endocrinol Metab, 2004,18 (4) : 531-554.
-
5Hoist J J, Deacon C F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors [ J ]. Diabetologia, 2005,48 (4) :612-615.
-
6Degn K B,Juhl C B,Sturis J,et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide ( NN2211 ) markedly improves 24 h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes [ J ]. Diabetes, 2004,53 ( 5 ) : 1187-1194.
-
7Emoto M, Nishiawa Y, Maekawa K, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas [ J ]. Diabetes Care, 1999,22 (5) :818-822.
-
8Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes ( LEAD-3 Mono) : randomised,52- week, phase Ⅲ, double-blind, parallel-treatment trial [ J ]. Lancet, 2009,373 ( 9662 ) :473- 481.
-
9Perfetti R,Zhou J, Doyle M E, et al. Glucagon-like peptide-1 induces cell proliferatin and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats[ J]. Endocrinology,2000,141 ( 12 ) :4600- 4605.
-
10Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes[ J]. Diabetes Care ,2007,30 ( 6 ) : 1608-1610.
-
1袁玉芳,杨晓春,何蓉,周文娣.利妥昔单抗联合地塞米松治疗小儿难治性特发性血小板减少性紫癜临床效果观察[J].中国小儿血液与肿瘤杂志,2012,17(4):174-176. 被引量：11
-
2刘向梅.小剂量利妥昔单抗治疗系统性红斑狼疮的作用分析[J].中外医疗,2015,34(13):142-143. 被引量：3
-
3汤浩.儿童糖尿病的胰岛素治疗[J].糖尿病之友,2009(6):41-41.
-
4韩学尧.胰岛B细胞功能受损到底能不能逆转?[J].药品评价,2011,8(5):45-45.
-
5顾明君.适当使用胰岛素 打破恶性循环[J].糖尿病之友,2008(4):28-28.
-
6宋作珪.胰岛素增敏剂在2型糖尿病中的应用[J].糖尿病之友,2004,0(2):20-21.
-
7李益明.B细胞功能受损的真正“元凶”[J].糖尿病天地,2005(4):26-27. 被引量：3
-
8杨晓平,林少达.糖尿病治疗药物与胰岛B细胞的保护[J].实用糖尿病杂志,2013,9(1):10-13. 被引量：2
-
9雷秀霞,萧正华,廖军,陈定宇.糖尿病足部感染患者血液超敏C反应蛋白和纤维蛋白原浓度变化[J].微循环学杂志,2006,16(3):69-69. 被引量：4
-
10付传发.CRP在COPD患者血清中的表达及与胰岛β细胞功能受损指标的相关性分析[J].医学临床研究,2016,33(12):2456-2458. 被引量：2
